Cartalax is a vendor-branded research peptide marketed within the broader Khavinson-bioregulator family for cartilage-tissue research. Unlike Cortagen or Bronchogen — both of which carry published peer-reviewed sequence assignments — Cartalax as a single defined molecule does not have a clean peer-reviewed PubMed-indexed sequence assignment under that specific brand name. This monograph lays out the Khavinson framework as it applies to connective-tissue research, the mechanism hypothesis the family rests on, the published evidence base on related cartilage-targeting tetrapeptides, and the substantial caveats around vendor-grade Cartalax identification.
Chemical identity and structure.
Cartalax, in the Khavinson research network's framework, is consistent with the broader Khavinson-bioregulator pattern — a short tetrapeptide derived by directed synthesis from cartilage-tissue extract sequence analysis. The precise sequence assignment under the "Cartalax" brand name is not unambiguously available in PubMed-indexed peer-reviewed literature. Researchers should expect a short tetrapeptide of approximately 400–500 g/mol molecular weight at the vendor level; the controlling identity for any specific vial is the COA's stated sequence, not the brand name. Related peer-reviewed Khavinson cartilage-and-connective-tissue work includes the AED tripeptide (Ala-Glu-Asp), which has been characterised in human-skin-fibroblast replicative-aging models for its effects on sirtuin-1, sirtuin-6, and collagen I expression — but this is not a sequence assignment for "Cartalax" itself.
Mechanism of action.
The Khavinson framework hypothesises that short peptides cross cell membranes, reach nuclear chromatin, and modulate gene expression in tissue-specific patterns determined by the peptide sequence — a hypothesis distinct from the receptor-pharmacology model that dominates most peptide research. For the cartilage-targeting compounds in the family, published mechanistic work describes effects on chondrocyte-marker gene expression, collagen-pathway modulation, and connective-tissue remodelling in preclinical models. The mechanism remains theoretical relative to the receptor-agonist standards used elsewhere in peptide research, and the strongest mechanistic data still comes from the Khavinson research network itself rather than independent replication.
Research applications and the evidence base.
Published research on Cartalax specifically is sparse and concentrates within the Khavinson group and a small number of international collaborators, most of it in Russian-language journals. The broader literature on Khavinson cartilage-and-connective-tissue peptide work covers preclinical osteoarthritis models, cartilage-biology gene-expression studies, and connective-tissue-aging questions in rodent models. Independent replication outside the Khavinson research network is limited. There are no completed Western Phase III human clinical trials of Cartalax, and the compound is not registered as a pharmaceutical therapy in any major Western jurisdiction. Anyone presenting Cartalax as a proven human therapy for joint or cartilage indications is overstating the underlying evidence.
Research context.
Cartalax sits within the broader Khavinson-bioregulator family alongside Epitalon (pineal, longevity research), Pinealon (CNS), Cortagen (cortex, Ala-Glu-Asp-Pro), Bronchogen (lung, Ala-Asp-Glu-Leu), Prostamax (prostate), and others. The compounds share discovery framework and mechanistic hypothesis but address different tissue systems; researchers working in the Khavinson paradigm typically choose the compound matching their target tissue. Cartalax is the cartilage-and-connective-tissue compound in that mapping — but unlike Cortagen or Bronchogen its sequence is not unambiguously published under that name, which is a meaningful evidence-quality distinction.
Storage and handling.
Lyophilized Cartalax should be kept refrigerated (2–8 °C) and protected from light. The peptide tolerates refrigerator-temperature storage reasonably well but does not tolerate repeated freeze-thaw cycles.
Human clinical trial data.
No human clinical trial has established administration parameters for Cartalax; VialTalk does not provide community-sourced dosing.
Quality and COA considerations.
A meaningful COA for a vendor-grade Cartalax vial must confirm identity via mass spectrometry and — most importantly — report the actual amino-acid sequence. Because there is no single unambiguous peer-reviewed sequence assignment under the "Cartalax" brand name, researchers should treat the COA's stated sequence as the controlling identity, not the brand name. Sequence-mislabelling between Khavinson tetrapeptides is a known quality issue in this market — Cortagen (Ala-Glu-Asp-Pro), Bronchogen (Ala-Asp-Glu-Leu), and various related short peptides are easily mislabelled when only the brand name appears on the vial. Purity by HPLC (≥98% benchmark) and sterility/endotoxin testing for any vial intended for injection-model use should also be reported.
Research-use note: This monograph is an educational summary of the Khavinson-bioregulator framework as it applies to vendor-grade Cartalax. The compound has limited unambiguous peer-reviewed sequence assignment under the "Cartalax" brand name, has not been evaluated in completed Western Phase III human clinical trials, and is not approved for human use in any major Western jurisdiction known to VialTalk. Nothing here is medical advice or a usage recommendation.
